Research Articles

Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.

stats1
stats2
stats3
stats4

Search for:

     Biguanide
25 records.
Article ID PMID Source Title Publish Year
A01811 34606980 Endocr Pract Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. 2021 Details
A09439 31749893 Diabetol Metab Syndr Long-term treatment with metformin in the prevention of fatty liver in Zucker diabetic fatty rats. 2019 Details
A10018 31523440 BMJ Open Gastroenterol Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia. 2019 Details
A12039 30628769 ACS Appl Mater Interfaces Targeted Interleukin-22 Gene Delivery in the Liver by Polymetformin and Penetratin-Based Hybrid Nanoparticles to Treat Nonalcoholic Fatty Liver Disease. 2019 Details
A12223 30556145 Hepatology Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. 2019 Details
A12514 30413050 Pharmaceuticals (Basel) Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? 2018 Details
A12888 30241400 Int J Mol Sci Metformin: An Old Drug with New Applications. 2018 Details
A17162 27939359 Pharmacol Res A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug? 2016 Details
A20122 26140084 World J Hepatol Systematic review: Preventive and therapeutic applications of metformin in liver disease. 2015 Details
A22122 24799988 World J Hepatol Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. 2014 Details
A22371 24633023 Intern Med Estimation of visceral fat and fatty liver disease using ultrasound in patients with diabetes. 2014 Details
A24655 25755424 J Clin Exp Hepatol Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. 2012 Details
A25499 21765869 Therap Adv Gastroenterol The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. 2011 Details
A26709 19921118 Adv Ther Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. 2009 Details
A28059 16540770 J Clin Gastroenterol Therapy of NAFLD: insulin sensitizing agents. 2006 Details
A28079 16672828 J Clin Gastroenterol Therapy of NAFLD: Insulin Sensitizing Agents. 2006 Details
A28165 16231594 Eur Rev Med Pharmacol Sci The treatment of NAFLD. 2006 Details
A36989 16768125 Nihon Rinsho [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. 2006 Details
A36990 16768123 Nihon Rinsho [Drug therapy for non-alcoholic steatohepatitis]. 2006 Details
A44501 28459036 Indian J Endocrinol Metab Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. 2020 Details
A48321 16762632 Gastroenterology Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. 2006 Details
A49024 21088486 Cell Cycle Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. 2010 Details
A52997 18154189 Clin Cornerstone Metabolic consequences of hyperglycemia and insulin resistance. 2007 Details
A53085 15262452 Clin Ther A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. 2004 Details
A53107 12930161 Drugs Metformin: new understandings, new uses. 2003 Details